Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| SCYNEXIS Inc. | Ibrexafungerp - (VANQUISH) | Vulvovaginal Candidiasis (VVC) | Phase 3 | Ongoing | oral | Anti-Fungal |
| SCYNEXIS Inc. | Ibrexafungerp - (MARIO) | Invasive candidiasis | Phase 3 | Trial Discontinued | Oral | Anti-Fungal |
| SCYNEXIS Inc. | BREXAFEMME (ibrexafungerp) - (SCYNERGIA) | Invasive aspergillosis | Phase 2 | Trial Discontinued | Oral | Anti-Fungal |
| Seelos Therapeutics Inc. | SLS-005 | Spinocerebellar Ataxia (SCA) | Phase 2/3 | Trial Discontinued | Intravenous | Neurology |
| Seelos Therapeutics Inc. | SLS-005 (IV trehalose) - (HEALEY ALS Platform Trial) | Amyotrophic lateral sclerosis (ALS) | Phase 2/3 | Data Released | Intravenous | Neurology |
| Seelos Therapeutics Inc. | SLS-002 (intranasal racemic ketamine) - (DOD M-PACT) | Post-traumatic stress disorder (PTSD) | Phase 2 | Ongoing | Intranasal | Psychiatric |
| Seelos Therapeutics Inc. | SLS-002 | Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder (ASIB in MDD) | Phase 2 | Type Meeting | Intranasal | Psychiatric |
| Seelos Therapeutics Inc. | Trehalose (SLS-005) | Sanfilippo syndrome/MPS III | Phase 2 | Intravenous | Genetic Disorder |
